A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants with Lichen Sclerosus

Recruiting
99 years or below
All
Phase N/A
4 participants needed

Brief description of study

This is a multi-site, interventional trial which evaluates the efficacy of delgocitinib cream for treating mild to severe lichen sclerosus (LS) in adults. The trial is conducted in 2 parts. Part 1 of the trial enrolls female participants with LS and results in the selection of the optimal dose for Part 2. The selected dose will then be evaluated in Part 2, which will enroll both female and male participants. Assessment of efficacy and safety of delgocitinib cream in male participants with LS will be evaluated in a substudy. The trial primarily focuses on female subjects, because LS is more likely to affect females than males. For each participant, the trial will last at least 55 weeks and up to 60 weeks.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 30 Sep 2026. Study ID: 26-7934

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center